Devon Patrick Ryan

Devon Patrick Ryan

Auto-generated profile, based on publicly available information

Devon Patrick Ryan

Max Planck Institute of Immunobiology and Epigenetics

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FNFrauke Neff
Frauke Neff
DFDiana Flores-Dominguez
Diana Flores-Dominguez
DRDevon P. Ryan
Devon P. Ryan
MHMarion Horsch
Marion Horsch
SSSusanne Schröder
Susanne Schröder
DEDan Ehninger
Dan Ehninger
Aging is a major risk factor for a large number of disorders and functional impairments. Therapeutic targeting of the aging process may therefore represent an innovative strategy in the quest for novel and broadly effective treatments against age-related diseases. The recent report of lifespan extension in mice treated with the FDA-approved mTOR inhibitor rapamycin represented the first demonstration of pharmacological extension of maximal lifespan in mammals. Longevity effects of rapamycin may, however, be due to rapamycin’s effects on specific life-limiting pathologies, such as cancers, and it remains unclear if this compound actually slows the rate of aging in mammals. Here, we present results from a comprehensive, large-scale assessment of a wide range of structural and functional aging phenotypes, which we performed to determine whether rapamycin slows the rate of aging in male C57BL/6J mice. While rapamycin did extend lifespan, it ameliorated few studied aging phenotypes. A subset of aging traits appeared to be rescued by rapamycin. Rapamycin, however, had similar effects on many of these traits in young animals, indicating that these effects were not due to a modulation of aging, but rather related to aging-independent drug effects. Therefore, our data largely dissociate rapamycin’s longevity effects from effects on aging itself.

1 January 2010 in Cell
Verified
Journal Article
Closed access
DRDevon P. Ryan
Devon P. Ryan
MSMagnus R. Dias Da Silva
Magnus R. Dias Da Silva
TSTuck Wah Soong
Tuck Wah Soong
BFBertrand Fontaine
Bertrand Fontaine
MDMatt R. Donaldson
Matt R. Donaldson
LPLouis J. Ptáček
Louis J. Ptáček

1 August 2013 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
RNR Nalavade
R Nalavade
NGN Griesche
N Griesche
DRD P Ryan
D P Ryan
SHS Hildebrand
S Hildebrand
SKSybille Krauss
Sybille Krauss
Several inherited neurodegenerative disorders are caused by CAG trinucleotide repeat expansions, which can be located either in the coding region or in the untranslated region (UTR) of the respective genes. Polyglutamine diseases (polyQ diseases) are caused by an expansion of a stretch of CAG repeats within the coding region, translating into a polyQ tract. The polyQ tract expansions result in conformational changes, eventually leading to aggregate formation. It is widely believed that the aggregation of polyQ proteins is linked with disease development. In addition, in the last couple of years, it has been shown that RNA-mediated mechanisms also have a profound role in neurotoxicity in both polyQ diseases and diseases caused by elongated CAG repeat motifs in their UTRs. Here, we review the different molecular mechanisms assigned to mRNAs with expanded CAG repeats. One aspect is the mRNA folding of CAG repeats. Furthermore, pathogenic mechanisms assigned to CAG repeat mRNAs are discussed. First, we discuss mechanisms that involve the sequestration of the diverse proteins to the expanded CAG repeat mRNA molecules. As a result of this, several cellular mechanisms are aberrantly regulated. These include the sequestration of MBNL1, leading to misregulated splicing; sequestration of nucleolin, leading to reduced cellular rRNA; and sequestration of proteins of the siRNA machinery, resulting in the production of short silencing RNAs that affect gene expression. Second, we discuss the effect of expanded CAG repeats on the subcellular localization, transcription and translation of the CAG repeat mRNA itself. Here we focus on the MID1 protein complex that triggers an increased translation of expanded CAG repeat mRNAs and a mechanism called repeat-associated non-ATG translation, which leads to proteins aberrantly translated from CAG repeat mRNAs. In addition, therapeutic approaches for CAG repeat disorders are discussed. Together, all the findings summarized here show that mutant mRNA has a fundamental role in the pathogenesis of CAG repeat diseases.

24 July 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
KXKan Xie
Kan Xie
FNFrauke Neff
Frauke Neff
AMAstrid Markert
Astrid Markert
JRJan Rozman
Jan Rozman
JAJuan Antonio Aguilar-Pimentel
Juan Antonio Aguilar-Pimentel
DEDan Ehninger
Dan Ehninger
Dietary restriction regimes extend lifespan in various animal models. Here we show that longevity in male C57BL/6J mice subjected to every-other-day feeding is associated with a delayed onset of neoplastic disease that naturally limits lifespan in these animals. We compare more than 200 phenotypes in over 20 tissues in aged animals fed with a lifelong every-other-day feeding or ad libitum access to food diet to determine whether molecular, cellular, physiological and histopathological aging features develop more slowly in every-other-day feeding mice than in controls. We also analyze the effects of every-other-day feeding on young mice on shorter-term every-other-day feeding or ad libitum to account for possible aging-independent restriction effects. Our large-scale analysis reveals overall only limited evidence for a retardation of the aging rate in every-other-day feeding mice. The data indicate that every-other-day feeding-induced longevity is sufficiently explained by delays in life-limiting neoplastic disorders and is not associated with a more general slowing of the aging process in mice.

15 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMoritz M Hettich
Moritz M Hettich
FMFrank Matthes
Frank Matthes
DRDevon P Ryan
Devon P Ryan
NGNadine Griesche
Nadine Griesche
SSSusanne Schröder
Susanne Schröder
DEDan Ehninger
Dan Ehninger
Alzheimer’s disease (AD), the most common form of dementia in the elderly, is characterized by two neuropathological hallmarks: senile plaques, which are composed of Aβ peptides, and neurofibrillary tangles, which are composed of hyperphosphorylated TAU protein. Diabetic patients with dysregulated insulin signalling are at increased risk of developing AD. Further, several animal models of diabetes show increased Aβ expression and hyperphosphorylated tau. As we have shown recently, the anti-diabetic drug metformin is capable of dephosphorylating tau at AD-relevant phospho-sites. Here, we investigated the effect of metformin on the main amyloidogenic enzyme BACE1 and, thus, on the production of Aβ peptides, the second pathological hallmark of AD. We find similar results in cultures of primary neurons, a human cell line model of AD and in vivo in mice. We show that treatment with metformin decreases BACE1 protein expression by interfering with an mRNA-protein complex that contains the ubiquitin ligase MID1, thereby reducing BACE1 activity. Together with our previous findings these results indicate that metformin may target both pathological hallmarks of AD and may be of therapeutic value for treating and/or preventing AD.

1 October 2010 in Neuron
Verified
Journal Article
Closed access
DRDevon P. Ryan
Devon P. Ryan
LPLouis J. Ptáček
Louis J. Ptáček